Recent Updates
Recently added Catalysts
CABA

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

Key Takeaway: PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger
Price reaction · baseline $3.35 (2022-11-21 close) · hit after-hours · clean, no other CABA news in the window
day 0 close · peak
+7.2%
day 1
+5.4%
day 3
+6%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
9.7%
average across 5 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
CABA-201
Phase 2 · Systemic Sclerosis

Full Press Release Details

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022 at 9:40 a.m. ET.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.
Chief Financial Officer
Stern Investor Relations, Inc.
Last updated: Nov 22, 2022